AstraZeneca scores much-needed clinical success

04:18 EDT 2 Aug 2017 | Proactive Investors

AstraZeneca PLC (LON:AZN) has scored some much needed clinical success following that may go some way to compensating for the failure of a much-hyped combination therapy for lung cancer. It has been granted a priority review by the US Food & Drug Administration (FDA) for acalabrutinib, which has been developed to treat a rare form of non-Hodgkin’s lymphoma. The new drug application is based on data from a phase II clinical trial on patients with relapsed and or refractory mantle cell lymphoma. It is incredibly rare to see a treatment jump from phase II to the regulatory sign-off stage in this way. Traditionally, a treatment must undergo a rigorous phase III test first. Priority review... Priority review status, meanwhile, is only granted to applications for medicines that, if approved, would offer a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. AZ’s acalabrutinib has also received breakthrough therapy designation from the FDA. The treatment is a highly-selective, potent, Bruton tyrosine kinase (BTK) inhibitor. BTK’s offer a breakthrough in treating blood-borne cancers. The success follows almost a week on from the abject failure of AZ’s MYSTIC study, which assessed the potential to use two of the company’s drugs to treat lung cancer. The bad news wiped around 15% off the share price.

Original Article: AstraZeneca scores much-needed clinical success


More From BioPortfolio on "AstraZeneca scores much-needed clinical success"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...